Unlock instant, AI-driven research and patent intelligence for your innovation.

Compsn contg. rutin and quercetin for preventing or treating elevated blood lipid level-related diseases

A technology of quercetin and composition, applied in the field of functional food or beverage compositions for treating or preventing such diseases, can solve problems such as expensive drugs, unfavorable side effects of central nervous system, etc.

Inactive Publication Date: 2001-10-17
KOREA RES INST OF BIOSCI & BIOTECH
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, these drugs are very expensive and their long-term administration is known to cause adverse side effects in the central nervous system
In addition, although lovastatin  and simvastatinPlasma LDL cholesterol levels can be lowered by enhancing the activity of LDL receptors in the liver, but they cause side effects such as increased creatine kinase in the liver and rhabdomyolysis (see Farmer, J.A., et al., Baillers-clin. Endocrinol. Metal., 9, 825-847 (1995))

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compsn contg. rutin and quercetin for preventing or treating elevated blood lipid level-related diseases
  • Compsn contg. rutin and quercetin for preventing or treating elevated blood lipid level-related diseases
  • Compsn contg. rutin and quercetin for preventing or treating elevated blood lipid level-related diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Further, the percentages given below for solids in solid mixtures, for liquids in liquids, and for solids in liquids are based on wt / wt, vol / vol, and wt / vol respectively, and unless otherwise stated, all reactions are at room temperature next. Example 1: Toxicity of Orally Administered Rutin

[0035] Twelve 7-week-old specific pathogen-free ICR female mice, including 6 female mice weighing about 25-29 g and 6 male mice weighing about 34-38 g, were kept at an ambient temperature of 22±1°C , relative humidity 55±5% and photoperiod 12L / 12D. Feed (Cheiljedang Co., rat and rabbit feed) and water were sterilized and fed to the mice.

[0036] Rutin commercially available from Aldrich-Sigma Chemical Co. (St.Louis, MO, U.S.A) was dissolved in 0.5% Tween 80 to a concentration of 100 mg / ml, and then the solution was orally administered to mice in an amount of 0.2ml / 20g mouse body weight. The solution was administered once to the mice, and the signs of adverse effects or death ...

Embodiment 2

[0038] diet group

[0039] During 6 weeks, the rats were allowed to eat the prescribed food and water freely, the daily intake was recorded, and the rats were weighed every 7 days, and then the records were analyzed. All rats showed normal growth rates, and there were no significant differences among the three groups in terms of food intake and weight gain. Step 2: Determination of Total Cholesterol, HDL-Cholesterol, and Neutral Lipids in Blood

[0040] The effects of administration of rutin or quercetin to rats on plasma cholesterol and neutral lipid levels were measured as follows.

[0041] Group

[0042] As can be seen from Table III, compared with the control group, the total plasma cholesterol levels in the rutin and quercetin groups were reduced by 21% and 30%, respectively. HDL-C / TC ratios were increased by 18% and 54% in the rutin and quercetin groups, respectively, compared to the control group. In addition, the neutral lipid content in the ruti...

Embodiment 3

[0043] To determine the effect of rutin-fed rats on ACAT activity, microsomes were isolated from ready-to-use liver tissue as the enzyme source.

[0044] Each 1g of liver from each group of rats in Example 2 was mixed in 5ml of homogenization medium (0.1MKH 2 PO 4 , pH7.4, 0.1mM EDTA and 10mM β-mercaptoethanol) homogenized. The homogenate was centrifuged at 3,000×g and 4°C for 15 minutes, and the obtained supernatant was centrifuged at 15,000×g and 4°C for 15 minutes to obtain a supernatant. The supernatant was placed in an ultracentrifuge tube (Beckman) and centrifuged at 100,000 x g at 4 °C to obtain a microsomal pellet, which was then suspended in 3 ml of homogenization medium and incubated at 100,000 x g and centrifuge at 4°C for 1 hour. The obtained precipitate was suspended in 1 ml of homogenization medium. The protein concentration in the resulting suspension was measured by Lowry's method and then adjusted to 4-8 mg / ml. The resulting suspension was stored in a cry...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

0A method for treating or preventing an elevated blood lipid level-related disease in a mammal, which comprises administering thereto an effective amount of rutin, quercetin or a mixture thereof.

Description

field of invention [0001] The present invention relates to a pharmaceutical composition for treating or preventing diseases associated with elevated blood lipid levels in mammals, such as hyperlipidemia, arteriosclerosis, angina pectoris, stroke and liver disease, the composition contains an effective amount of active rutin (rutin) or quercetin (quercetin) of composition and pharmaceutically acceptable carrier; The present invention also relates to the functional food or beverage composition that is used for treating or preventing this kind of disease, and it contains effective amount of rutin or Quercetin. Background of the invention [0002] It has been reported that blood lipids, especially cholesterol and triglycerides, are closely related to various diseases such as coronary heart circulation diseases, such as arteriosclerosis and hypercholesterolemia, and fatty liver. Cholesterol, a fatty sterol, is a blood lipid produced in the liver from saturated fat. Triglyceride...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A21D2/14A21D2/36A21D13/00A21D13/08A23C9/13A23C9/152A23C19/093A23F3/14A23G1/00A23G1/30A23G3/00A23G3/34A23G4/00A23G9/32A23G9/44A23G9/52A23L1/30A23L2/02A23L2/52A23L7/109A23L13/40A23L23/00A23L27/60A23L33/15A23L35/00A61K31/352A61K31/70A61K31/7042A61K31/7048A61K36/00A61P3/06A61P9/10C07D311/30C07H17/07C12G3/00
CPCA21D2/14A23C9/13A23L1/243A23L1/31445A23L1/39A23L2/52A23L1/16A23C9/152Y10S514/824A61K31/70A23L7/109A23L27/63A23L13/428A23L23/00A61P3/06A61P9/10A61K2300/00
Inventor 卜成海郑泰淑裴基焕朴镛福崔明淑文锡植权容国李恩淑玄柄和崔良圭李哲浩李世峰朴永培金孝洙
Owner KOREA RES INST OF BIOSCI & BIOTECH